Patents Assigned to PHARMAKEA, INC.
  • Uses of a lysyl oxidase-like 2 inhibitor
    Patent number: 11793797
    Abstract: Described herein is the use of a LOXL2 inhibitor in the treatment or prevention of conditions, diseases, or disorders associated with LOXL2 activity.
    Type: Grant
    Filed: September 6, 2017
    Date of Patent: October 24, 2023
    Assignee: PHARMAKEA, INC.
    Inventors: Gretchen Bain, Jillian Frances Evans, Deidre A. Mackenna, John Howard Hutchinson
  • Crystalline forms of a lysyl oxidase-like 2 inhibitor and methods of making
    Patent number: 11459309
    Abstract: Described herein are crystalline forms of pharmaceutically acceptable salts of the lysyl oxidase-like 2 (LOXL2) inhibitor (3-(4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yloxy)phenyl)((3R,4R)-3-fluoro-4-hydroxypyrrolidin-1-yl)methanone. Also described are methods of making the LOXL2 inhibitor, pharmaceutical compositions and medicaments comprising the LOXL2 inhibitor, and methods of using the LOXL2 inhibitor in the treatment of conditions, diseases, or disorders associated with LOXL2 activity.
    Type: Grant
    Filed: August 3, 2020
    Date of Patent: October 4, 2022
    Assignee: PHARMAKEA, INC.
    Inventors: David Lonergan, Kevin Ross Holme, Martin W. Rowbottom
  • Lysyl oxidase-like 2 inhibitors and uses thereof
    Patent number: 11358936
    Abstract: Described herein are compounds that are LOXL2 inhibitors, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with LOXL2 activity.
    Type: Grant
    Filed: July 17, 2020
    Date of Patent: June 14, 2022
    Assignee: PharmAkea, Inc.
    Inventors: Martin W. Rowbottom, John Howard Hutchinson, David Lonergan
  • Apoptosis signal-regulating kinase 1 (ASK 1) inhibitor compounds
    Patent number: 11345676
    Abstract: Described herein are ASK1 inhibitors, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with ASK1 activity.
    Type: Grant
    Filed: March 23, 2018
    Date of Patent: May 31, 2022
    Assignee: PHARMAKEA, INC.
    Inventor: Martin W. Rowbottom
  • Fluorinated lysyl oxidase-like 2 inhibitors and uses thereof
    Patent number: 11072585
    Abstract: Described herein are compounds that are LOXL2 inhibitors, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with LOXL2 activity.
    Type: Grant
    Filed: December 13, 2019
    Date of Patent: July 27, 2021
    Assignee: PHARMAKEA, INC.
    Inventors: Martin W. Rowbottom, John Howard Hutchinson, Imelda Calderon
  • Quinolinone lysyl oxidase-like 2 inhibitors and uses thereof
    Patent number: 11058676
    Abstract: Described herein are compounds that are LOXL2 inhibitors, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with LOXL2 activity.
    Type: Grant
    Filed: August 27, 2019
    Date of Patent: July 13, 2021
    Assignee: PHARMAKEA, INC.
    Inventors: Martin W. Rowbottom, John Howard Hutchinson
  • Crystalline forms of a lysyl oxidase-like 2 inhibitor and methods of making
    Patent number: 10774069
    Abstract: Described herein are crystalline forms of pharmaceutically acceptable salts of the lysyl oxidase-like 2 (LOXL2) inhibitor (3-(4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yloxy)phenyl)((3R,4R)-3-fluoro-4-hydroxypyrrolidin-1-yl)methanone. Also described are methods of making the LOXL2 inhibitor, pharmaceutical compositions and medicaments comprising the LOXL2 inhibitor, and methods of using the LOXL2 inhibitor in the treatment of conditions, diseases, or disorders associated with LOXL2 activity.
    Type: Grant
    Filed: September 6, 2017
    Date of Patent: September 15, 2020
    Assignee: PHARMAKEA, INC.
    Inventors: David Lonergan, Kevin Ross Holme, Martin W. Rowbottom
  • Lysyl oxidase-like 2 inhibitors and uses thereof
    Patent number: 10766860
    Abstract: Described herein are compounds that are LOXL2 inhibitors, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with LOXL2 activity.
    Type: Grant
    Filed: March 3, 2016
    Date of Patent: September 8, 2020
    Assignee: PHARMAKEA, INC.
    Inventors: Martin W. Rowbottom, John Howard Hutchinson, David Lonergan
  • Quinolinone lysyl oxidase-like 2 inhibitors and uses thereof
    Patent number: 10588900
    Abstract: Described herein are compounds that are LOXL2 inhibitors, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with LOXL2 activity.
    Type: Grant
    Filed: February 7, 2017
    Date of Patent: March 17, 2020
    Assignee: PHARMAKEA, INC.
    Inventors: Martin W. Rowbottom, John Howard Hutchinson
  • Fluorinated lysyl oxidase-like 2 inhibitors and uses thereof
    Patent number: 10570094
    Abstract: Described herein are compounds that are LOXL2 inhibitors, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with LOXL2 activity.
    Type: Grant
    Filed: September 21, 2018
    Date of Patent: February 25, 2020
    Assignee: PHARMAKEA, INC.
    Inventors: Martin W. Rowbottom, John Howard Hutchinson, Imelda Calderon
  • Fluorinated lysyl oxidase-like 2 inhibitors and uses thereof
    Patent number: 10150732
    Abstract: Described herein are compounds that are LOXL2 inhibitors, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with LOXL2 activity.
    Type: Grant
    Filed: September 5, 2017
    Date of Patent: December 11, 2018
    Assignee: PHARMAKEA, INC.
    Inventors: Martin W. Rowbottom, John Howard Hutchinson, Imelda Calderon
  • Autotaxin inhibitor compounds
    Patent number: 9999615
    Abstract: Described herein are compounds that are autotaxin inhibitors, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with autotaxin activity.
    Type: Grant
    Filed: September 9, 2016
    Date of Patent: June 19, 2018
    Assignee: PHARMAKEA, INC.
    Inventors: John Howard Hutchinson, David Lonergan
  • AUTOTAXIN INHIBITORS AND USES THEREOF
    Publication number: 20180147185
    Abstract: Described herein are methods and compositions for the treatment of conditions, diseases, or disorders associated with autotaxin activity. The methods and compositions disclosed herein include the use of at least one autotaxin inhibitor compound.
    Type: Application
    Filed: May 24, 2016
    Publication date: May 31, 2018
    Applicant: PharmAkea, Inc.
    Inventors: Gretchen BAIN, Jillian Frances EVANS, John Howard HUTCHINSON, David LONERGAN
  • Heterocyclic vinyl autotaxin inhibitor compounds
    Patent number: 9951026
    Abstract: Described herein are compounds that are autotaxin inhibitors, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with autotaxin activity.
    Type: Grant
    Filed: September 16, 2014
    Date of Patent: April 24, 2018
    Assignee: PHARMAKEA, INC.
    Inventors: John Howard Hutchinson, Timothy Andrew Parr, Kevin Duane Bunker, David Lonergan
  • Tetracyclic autotaxin inhibitors
    Patent number: 9926318
    Abstract: Described herein are compounds that are autotaxin inhibitors, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with autotaxin activity.
    Type: Grant
    Filed: November 20, 2014
    Date of Patent: March 27, 2018
    Assignee: PHARMAKEA, INC.
    Inventors: John Howard Hutchinson, David Lonergan, Martin Rowbottom, Andiliy Gokching Lai
  • Autotaxin inhibitor compounds
    Patent number: 9850203
    Abstract: Described herein are compounds that are autotaxin inhibitors, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with autotaxin activity.
    Type: Grant
    Filed: September 25, 2014
    Date of Patent: December 26, 2017
    Assignee: PHARMAKEA, INC.
    Inventors: John Howard Hutchinson, David Lonergan, Fei Huang, Martin Rowbottom, Imelda Calderon
  • Vinyl autotaxin inhibitor compounds
    Patent number: 9714240
    Abstract: Described herein are compounds that are autotaxin inhibitors, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with autotaxin activity.
    Type: Grant
    Filed: September 16, 2014
    Date of Patent: July 25, 2017
    Assignee: PHARMAKEA, INC.
    Inventors: John Howard Hutchinson, Timothy Andrew Parr, David Lonergan
  • Autotaxin inhibitor compounds
    Patent number: 9468628
    Abstract: Described herein are compounds that are autotaxin inhibitors, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with autotaxin activity.
    Type: Grant
    Filed: March 3, 2016
    Date of Patent: October 18, 2016
    Assignee: PHARMAKEA, INC
    Inventors: John Howard Hutchinson, David Lonergan
  • Autotaxin inhibitor compounds
    Patent number: 9334261
    Abstract: Described herein are compounds that are autotaxin inhibitors, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with autotaxin activity.
    Type: Grant
    Filed: October 29, 2015
    Date of Patent: May 10, 2016
    Assignee: PHARMAKEA, INC.
    Inventors: John Howard Hutchinson, David Lonergan
  • Methods for the treatment of metabolic disorders by a selective small molecule autotaxin inhibitor
    Patent number: 9051320
    Abstract: Described herein are methods and compositions for treatment or prevention of metabolic disorder(s) in an individual. The methods and compositions disclosed herein include the use of at least one autotaxin inhibitor compound.
    Type: Grant
    Filed: August 18, 2014
    Date of Patent: June 9, 2015
    Assignee: PHARMAKEA, INC.
    Inventor: Jillian Frances Evans